Distribution of high-risk human r slloanvsrmsr e oiy e

Introduction

2 b 9 da P 2P R aA b PaR 0 dVdbc

CareHPV testing (Qiagen, Gaithersburg, MD, USA)
Care

HPV test with genotyping (Sansure, Changsha, China)

care

PCR-based HPV testing without genotyping (Sansure, Changsha, China)

in situ

care

Figure 1




Figure 1

Table 1

Characteristics	Normal	CIN1	CIN2	CIN3+	^{2}	P
Age (year)						
≤47	4,885	51	27	14	3.172	0.366
>47	4,367	52	29	21		
Education level						
No education	607	12	5	2	4.777*	0.171
Educated						

Table 2

Table 2

HR-HPV genotype	Normal pathology (n=9,252)			CIN1 (n=103)			CIN2+ (n=91)			Total population (n=9,526)***		
	n (%)*	Single infection (n)	Attributable proportion(%)**	n (%)*	Single infection (n)	Attributable proportion (%)**	n (%)*	Single infection (n)	Attributable proportion (%)**	n (%)*	Single infection (n)	Attributable proportion (%)**
Any type	1,611	951	100.00	98	50	100.00	90	49	100.00	1,874	1,089	100.00
16	187 (11.61)	84	8.09	36 (36.73)	13	30.68	68 (75.56)	37	73.53	303 (16.17)	140	12.09
18	83 (5.15)	26	2.27	12 (12.24)	3	5.64	6 (6.67)	0	0.37	105 (5.60)	31	2.41
31	113 (7.01)	45	4.02	8 (8.16)	2	3.40	8 (8.89)	1	1.68	137 (7.31)	49	3.91
33	141 (8.75)	53	5.22	8 (8.16)	1	2.01	9 (10.00)	1	3.42	164 (8.75)	56	4.71
35	66 (4.10)	16	1.45	3 (3.06)	1	1.13	3 (3.33)	1	1.17	75 (4.00)	19	1.45
39	152 (9.44)	27										

P cP 7A7 bca dc P Pca dc

Figure 3

Figure 3

Discussion

care

Acknowledgements

Footnote

Conflicts of Interest

References